PolyMedix Progresses With Drug That Mimics Body’s Natural Protective Proteins
This article was originally published in Pharmaceutical Approvals Monthly
Novel antibiotic brilacidin meets endpoints in Phase IIa study of 215 patients with acute bacterial skin and skin structure infection. Design went further than requirements in FDA guidance for ABSSSI.
You may also be interested in...
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
With brilacidin developer PolyMedix having filed for bankruptcy, Cellceutix will acquire the company’s assets for $2.1 million in cash and 1.4 million shares of stock.
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials